Yabao Pharmaceutical Group Co., Ltd (SHA:600351)

Market Cap	4.56B +11.9%
Revenue (ttm)	2.20B -13.1%
Net Income	319.41M +34.4%
EPS	0.46 +38.1%
Shares Out	692.00M
PE Ratio	14.36
Forward PE	n/a
Dividend	0.50 (7.59%)
Ex-Dividend Date	Feb 6, 2026

Volume	9,776,000
Average Volume	21,626,878
Open	6.57
Previous Close	6.59
Day's Range	6.45 - 6.57
52-Week Range	5.86 - 8.68
Beta	0.11
RSI	41.40
Earnings Date	Apr 25, 2026

About SHA:600351

Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, APIs, and pharmaceutical packaging materials in China and internationally. The company provides products for pediatrics, female healthcare, cardiovascular, big health, and elderly chronic diseases under the Diarrago, Baiyu, and Yabao brands. It also offers plastic bottles and cartons. The company provides its products in the form of injections, tablets, capsules, granules, pills, patches, freeze-dried powders, mixtures, suppositories...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 3,415
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600351

Financial Performance

In 2025, SHA:600351's revenue was 2.24 billion, a decrease of -16.60% compared to the previous year's 2.69 billion. Earnings were 320.01 million, an increase of 31.86%.